The Innovation at a Glance
US11524048B2 introduces a sophisticated treatment approach for severe sepsis through the selective degradation of HMGB1 protein using proteolysis targeting chimera (PROTAC) compounds. This method employs targeted protein degradation to address a key pathological driver of sepsis, a condition with a persistent high mortality rate and limited effective therapies. The patent reflects strong therapeutic novelty by focusing on HMGB1 antagonism, leveraging advanced biochemical techniques for targeted intervention.
The Inventor & Company Behind It
The patent is assigned to the Feinstein Institutes for Medical Research, a well-regarded entity in medical innovation and biopharmaceutical research. Their expertise in translational health technology is evident in the high technical complexity of this invention. Feinstein Institutes’ strategic positioning in biomedicine strengthens its ability to both develop and license technologies aimed at major healthcare challenges like sepsis.
Market Opportunity
Severe sepsis remains a critical clinical challenge globally with substantial unmet medical need. Treatments that can effectively intervene at the molecular level to mitigate the condition’s progression are poised to disrupt the market. The selective degradation of HMGB1 has the potential to address underlying inflammatory pathways, offering a novel therapeutic angle that could complement or outperform existing supportive care approaches, thereby opening significant commercial avenues.
Growth Indicators
This patent’s citation count of 278 indicates strong recognition and influence within the relevant scientific and IP community. An HIS score of 84.1 underlines the patent's robustness, relevance, and potential market impact. These metrics signal that US11524048B2 occupies a prominent position in evolving proteolysis targeting chimera technologies related to critical disease treatment.
Why IP Investors Are Watching
The intersection of PROTAC technology with a high unmet need indication like severe sepsis places this patent in a favorable licensing and collaboration position. The high technical threshold and therapeutic novelty reduce competitive encroachment risk. However, investors should note the early stage of development and potential regulatory complexities typical in novel biologics. Overall, the patent’s breadth and strong citation footprint make it a compelling asset for those targeting frontier biopharma innovation focused on life-threatening conditions.
Get the Full Analysis
For a comprehensive evaluation of US11524048B2’s claims, market potential, and strategic fit within the biopharma IP landscape, IPI Terminal provides detailed analytics and ongoing tracking. This patent exemplifies the type of cutting-edge health technology IP warranted by investors aiming to identify foundational assets in complex therapeutic areas.